Needham analyst Serge Belanger has maintained their bullish stance on BCRX stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Serge Belanger has given his Buy rating due to a combination of factors that highlight BioCryst’s potential for growth and market expansion. The recent FDA approval of the pediatric formulation of Orladeyo significantly broadens the drug’s market reach, allowing it to be used in pediatric patients with hereditary angioedema (HAE) in the United States. This approval opens up a new patient demographic of approximately 500 individuals who previously had limited prophylactic therapy options.
Additionally, Belanger’s analysis takes into account BioCryst’s strategic business decisions, such as the divestment of its European operations and the acquisition of Astria, which are expected to positively impact the company’s financial performance. The valuation of BioCryst, according to Belanger, does not fully reflect the current sales levels and the robust growth potential of Orladeyo, justifying the Buy rating and the price target of $18.
Belanger covers the Healthcare sector, focusing on stocks such as BioCryst, Cormedix, and Cytokinetics. According to TipRanks, Belanger has an average return of 14.6% and a 50.89% success rate on recommended stocks.
In another report released today, Wedbush also maintained a Buy rating on the stock with a $21.00 price target.